Cargando…
The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
OBJECTIVE: To determine the combination of fasting blood glucose (FBG) with squamous cell carcinoma antigen (SCCA) assessments in the prediction of tumor responses to chemotherapy and pretreatment prognostication among patients receiving neoadjuvant chemotherapy (NACT) for locally advanced cervical...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718550/ https://www.ncbi.nlm.nih.gov/pubmed/31310455 http://dx.doi.org/10.1002/cam4.2414 |
_version_ | 1783447742619582464 |
---|---|
author | Wu, Miao‐Fang Guan, Mei‐Mei Liu, Chang‐Hao Wu, Jie‐Ying Rao, Qun‐Xian Li, Jing |
author_facet | Wu, Miao‐Fang Guan, Mei‐Mei Liu, Chang‐Hao Wu, Jie‐Ying Rao, Qun‐Xian Li, Jing |
author_sort | Wu, Miao‐Fang |
collection | PubMed |
description | OBJECTIVE: To determine the combination of fasting blood glucose (FBG) with squamous cell carcinoma antigen (SCCA) assessments in the prediction of tumor responses to chemotherapy and pretreatment prognostication among patients receiving neoadjuvant chemotherapy (NACT) for locally advanced cervical cancer (LACC). METHODS: Data of 347 LACC patients were retrospectively reviewed. Receiver operating characteristic (ROC) curves were constructed, and areas under the curves (AUCs) were compared to evaluate the ability to predict complete response (CR) following NACT. Patients were stratified into groups with low and high levels of SCCA and FBG and combined into low‐ or high‐SCCA and low‐ or high‐FBG groups. Cox regression analysis was performed to identify determinants of recurrence‐free survival (RFS) and overall survival (OS). RESULTS: The AUCs were 0.70, 0.68, and 0.66 for SCCA, FBG, and a combination of SCCA and FBG for predicting CR following NACT, respectively; however, the differences among AUCs were not significant (P = .496). Pretreatment SCCA and FBG levels were identified as independent predictors of RFS and OS. The high‐SCCA/high‐FBG group showed significantly worse prognosis than the low‐SCCA/low‐FBG group. After adjusting for other variables, high‐SCCA/high‐FBG remained independently associated with an increased risk of tumor recurrence and death. CONCLUSION: SCCA, FBG, and a combination of SCCA and FBG could acceptably predict CR following NACT. Pretreatment SCCA and FBG levels were independent prognostic factors. The combination of SCCA and FBG levels refined the prognostic stratification of LACC patients, which allowed the group of patients with the highest risk of recurrence and death to be identified. |
format | Online Article Text |
id | pubmed-6718550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67185502019-09-06 The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy Wu, Miao‐Fang Guan, Mei‐Mei Liu, Chang‐Hao Wu, Jie‐Ying Rao, Qun‐Xian Li, Jing Cancer Med Clinical Cancer Research OBJECTIVE: To determine the combination of fasting blood glucose (FBG) with squamous cell carcinoma antigen (SCCA) assessments in the prediction of tumor responses to chemotherapy and pretreatment prognostication among patients receiving neoadjuvant chemotherapy (NACT) for locally advanced cervical cancer (LACC). METHODS: Data of 347 LACC patients were retrospectively reviewed. Receiver operating characteristic (ROC) curves were constructed, and areas under the curves (AUCs) were compared to evaluate the ability to predict complete response (CR) following NACT. Patients were stratified into groups with low and high levels of SCCA and FBG and combined into low‐ or high‐SCCA and low‐ or high‐FBG groups. Cox regression analysis was performed to identify determinants of recurrence‐free survival (RFS) and overall survival (OS). RESULTS: The AUCs were 0.70, 0.68, and 0.66 for SCCA, FBG, and a combination of SCCA and FBG for predicting CR following NACT, respectively; however, the differences among AUCs were not significant (P = .496). Pretreatment SCCA and FBG levels were identified as independent predictors of RFS and OS. The high‐SCCA/high‐FBG group showed significantly worse prognosis than the low‐SCCA/low‐FBG group. After adjusting for other variables, high‐SCCA/high‐FBG remained independently associated with an increased risk of tumor recurrence and death. CONCLUSION: SCCA, FBG, and a combination of SCCA and FBG could acceptably predict CR following NACT. Pretreatment SCCA and FBG levels were independent prognostic factors. The combination of SCCA and FBG levels refined the prognostic stratification of LACC patients, which allowed the group of patients with the highest risk of recurrence and death to be identified. John Wiley and Sons Inc. 2019-07-16 /pmc/articles/PMC6718550/ /pubmed/31310455 http://dx.doi.org/10.1002/cam4.2414 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Wu, Miao‐Fang Guan, Mei‐Mei Liu, Chang‐Hao Wu, Jie‐Ying Rao, Qun‐Xian Li, Jing The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy |
title | The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy |
title_full | The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy |
title_fullStr | The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy |
title_full_unstemmed | The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy |
title_short | The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy |
title_sort | added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718550/ https://www.ncbi.nlm.nih.gov/pubmed/31310455 http://dx.doi.org/10.1002/cam4.2414 |
work_keys_str_mv | AT wumiaofang theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT guanmeimei theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT liuchanghao theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT wujieying theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT raoqunxian theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT lijing theaddedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT wumiaofang addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT guanmeimei addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT liuchanghao addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT wujieying addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT raoqunxian addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy AT lijing addedvalueoffastingbloodglucosetoserumsquamouscellcarcinomaantigenforpredictingoncologicaloutcomesincervicalcancerpatientsreceivingneoadjuvantchemotherapyfollowedbyradicalhysterectomy |